Predictive value of Dmax and %ΔSUVmax of 18F-FDG PET/CT for the prognosis of patients with diffuse large B-cell lymphoma

被引:1
|
作者
Dang, Jun [1 ]
Peng, Xiaojuan [1 ]
Wu, Ping [1 ]
Yao, Yutang [1 ]
Tan, Xiaofei [1 ]
Ye, Zhenyan [1 ]
Jiang, Xuemei [1 ]
Jiang, Xiao [1 ]
Liu, Yongli [1 ]
Chen, Shirong [1 ]
Cheng, Zhuzhong [1 ]
机构
[1] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Dept Nucl Med,Sichuan Clin Res Ctr Canc,Affiliated, Chengdu, Peoples R China
关键词
Diffuse large B-cell lymphoma; F-18-fluoro-deoxyglucose; Positron emission tomography; Prognosis; POSITRON-EMISSION-TOMOGRAPHY; PROGRESSION-FREE SURVIVAL; METABOLIC TUMOR VOLUME; INTERIM; RECOMMENDATIONS;
D O I
10.1186/s12880-023-01138-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To investigate the prognosis value of a combined model based on F-18-fluoro-deoxyglucose positron emission tomography-computed tomography (F-18-FDG PET-CT) baseline and interim parameters in patients with diffuse large B-cell lymphoma (DLBCL). Methods We retrospectively analyzed the PET metabolic parameters and clinical data of 154 DLBCL patients between December 2015 and October 2020. All of these patients underwent F-18-FDG PET/CT scan before treatment and after three or four courses of chemotherapy. The optimal cut-off values for quantitative variables were determined by the receiver operating characteristic (ROC) curve. The baseline and interim PET/CT parameters, which respectively included maximum standardized uptake value (SUVmax0), total metabolic tumor volume (TMTV0), standardized total metabolic tumor volume (STMTV0), and the distance between the two furthest lesions (Dmax) and total tumor lesion glycolysis (TTLG1), SUVmax1, TMTV1, and the rate of change of SUVmax (%Delta SUVmax), and clinical characteristics were analyzed by chi-squared test, Kaplan-Meier survival curve, and Cox regression analysis. Results Of 154 patients, 35 exhibited disease progression or recurrence. ROC analysis revealed that baseline F-18-FDG PET/CT metabolic parameters, including maximum standardized uptake value (SUVmax0), total metabolic tumor volume (TMTV0), standardized total metabolic tumor volume (STMTV0), and the distance between the two furthest lesions (Dmax), along with interim F-18-FDG PET/CT metabolic parameters such as total tumor lesion glycolysis (TTLG1), SUVmax1, TMTV1, and the rate of change of SUVmax (%Delta SUVmax), were predictive of relapse or progression in DLBCL patients (P < 0.05). The chi-squared test showed that TMTV0, STMTV0, Dmax, SUVmax1, TMTV1, TTLG1, %Delta SUVmax, Deauville score, IPI, Ann Arbor stage, and LDH were associated with patient prognosis (P < 0.05). Multivariate Cox regression analysis showed that Dmax (P = 0.021) and %Delta SUVmax (P = 0.030) were independent predictors of prognosis in DLBCL patients. There were statistically significant differences in PFS among the three groups with high, intermediate, and low risk according to the combination model (P < 0.001). The combination model presented higher predictive efficacy than single indicators. Conclusion The combined model of baseline parameter Dmax and intermediate parameter %Delta SUVmax of F-18-FDG PET/CT improved the predictive efficacy of PFS and contributed to the risk stratification of patients, providing a reference for clinical individualization and precision treatment.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] The value of 18F-FDG PET/CT in evaluating the efficacy of chemotherapy for diffuse large B-cell lymphoma with cardiac involvement
    Yang, Yuhua
    Chen, Peiyin
    Liu, Lisha
    Lin, Juyi
    Huang, Shengcai
    JOURNAL OF NUCLEAR CARDIOLOGY, 2022, 29 (06) : 3548 - 3553
  • [22] Preliminary study on the application value of 18F-FDG PET/CT in diffuse large B-cell lymphoma immunological subtypes
    Liu, Meng
    Wang, Rong Fu
    Zhang, Jianhua
    Chen, Xueqi
    Fu, Zhanli
    Fan, Yan
    Zhang, Xuchu
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [23] Application value of 18F-FDG PET/CT metabolic parameters in the prognostic prediction of Diffuse Large B-cell Lymphoma
    Li, J.
    Sun, X.
    Li, Y.
    Yang, J.
    Zhao, Q.
    Yang, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S558 - S558
  • [24] Panaortitis diagnosed by 18F-FDG PET/CT scan in a patient with diffuse large B-cell lymphoma
    Roldan Valadez, E.
    Vega-Gonzalez, I.
    Valdivieso-Cardenas, G.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2007, 26 (04): : 232 - 233
  • [25] Pretherapy and posttherapy 18F-FDG PET/CT in isolated nasoseptal diffuse large B-cell lymphoma
    Asa, S.
    Aliyev, A.
    Yilmaz, S.
    Erkan, M. E.
    Sager, S.
    Halac, M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2013, 32 (01): : 62 - 63
  • [26] Unusually Elevated Gastric Radioactivity on 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma
    Yin, Hongyan
    Liu, Guobing
    Xiu, Yan
    Luo, Rongkui
    Shi, Hongcheng
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (07) : 512 - 514
  • [27] Primary diffuse large B-cell lymphoma of seminal vesicles detected by 18F-FDG PET/CT
    Gong, Weidong
    Yang, Xiao
    Wu, Junhao
    Ou, Lei
    Zhang, Chunyin
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2021, 24 (02): : 163 - 164
  • [28] The Central Cavitation in Pulmonary Diffuse Large B-Cell Lymphoma Detected by 18F-FDG PET/CT
    Lin, Nan
    Xie, Hangyu
    Zhang, Wenjie
    Ma, Xuelei
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (06) : 562 - 563
  • [29] The prognostic value of splenic abnormalities in pretreatment 18F-FDG PET/CT in patients with complete response diffuse large B-cell lymphoma
    Wang, S.
    Ju, H.
    Bai, Y.
    Wang, L.
    Ding, Q.
    Li, P.
    Jiang, X.
    Lin, X.
    CLINICAL RADIOLOGY, 2023, 78 (05) : 375 - 380
  • [30] Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline 18F-FDG PET-CT
    Delaby, Gauthier
    Hubaut, Marc-Antoine
    Morschhauser, Franck
    Besson, Alix
    Huglo, Damien
    Herbaux, Charles
    Baillet, Clio
    LEUKEMIA & LYMPHOMA, 2020, 61 (07) : 1584 - 1591